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Human papillomaviruses (HPV) of the genera alpha, mu, and nu induce benign tumors of the cutaneous
epithelia that constitute a significant burden for immunocompromised adults. Currently, no gold standard for
genotyping of these HPV types exists. In this study, we describe the prevalence of genus alpha, mu, and nu HPV
types in cutaneous warts. We developed a novel multiplex HPV genotyping assay, BSwart-PCR/MPG (BSwart),
to type sensitively and specifically 19 cutaneous HPV types frequently found in warts. BSwart-PCR/MPG is
based on a multiplex PCR using broad-spectrum primers and subsequent multiplex hybridization to type-
specific probes coupled to Luminex beads. In a first application comprising 100 cutaneous warts, the assay was
compared to another, recently described genotyping assay, the HSL-PCR/MPG. When a 10-fold dilution series
was used, the detection limit was between 10 and 100 HPV genomes per PCR. When comparing the two assays,
there was an excellent agreement in detecting dominant HPV types; however, we also obtained evidence for a
higher sensitivity of the BSwart assay for multiple infections in these cutaneous warts. Using BSwart, HPV was
found in 95% of wart preparations, with HPV1 being most prevalent, followed by types 27, 57, and 2. Both novel
BSwart and HSL-PCR/MPG HPV genotyping assays are powerful high-throughput tools that could be used to
learn more about the natural history of cutaneous HPV. They would be advantageous to monitor the efficacy
of future skin HPV vaccines and to identify novel HPV vaccine candidates.
Human papillomaviruses (HPV) are a group of DNA viruses
with more than 110 distinct genotypes characterized so far.
Based on sequence relatedness, the HPV phylogenetic tree is
composed of five genera (alpha, beta, gamma, mu, and nu
papillomaviruses), which, in turn, are grouped into species and
subdivided into types (2). Human papillomaviruses infect ei-
ther cutaneous or mucosal epithelium. While the so-called
high-risk HPV types within the mucosal genus alpha are asso-
ciated with cancers of the uterine cervix, cutaneous HPV types
of genus beta are associated with cutaneous squamous cell
carcinoma (SCC) in patients with the rare hereditary skin
disease epidermodysplasia verruciformis (EV) (6). Cutaneous
genus alpha HPV cause benign skin lesions, such as common,
flat, or plantar warts (5). These warts are common during
childhood but constitute a significant burden for immuno-
compromised adults. For example, organ transplant recipi-
ents frequently suffer from their confluent occurrence at
multiple body sites (3). As a consequence, prophylactic cu-
taneous genus alpha HPV vaccines are currently being de-
veloped for patients receiving organ transplantation or im-
munosuppression (11, 12).
Hitherto, PCR-based assays using type-specific or degener-
ate primers have been applied to detect and identify different
cutaneous genus alpha HPV types (4). However, in order to
perform HPV genotyping, these methods rely on sequencing of
PCR products or cloned PCR products, which is a time-inten-
sive procedure. To overcome the drawbacks as referred to
above, a novel high-throughput multiplex broad-spectrum
HPV genotyping (MPG) procedure, the HSL-PCR/MPG as-
say, has been described recently to genotype 23 distinct HPV
types, with a type-specific analytical sensitivity of 10 to 10,000
copies per reaction (1).
At the same time, a similar Luminex-based MPG assay, the
multiplex BSwart-PCR/MPG (BSwart) assay for the detection
of the genus alpha, mu, and nu HPV types 1, 2, 3, 6, 7, 10, 11,
27, 28, 29, 40, 41, 43, 57, 63, 77, 91, 94, and 117, had been
designed at the German Cancer Research Center. In this pa-
per, the development of the BSwart assay and the cross-vali-
dation with the HSL-PCR/MPG assay, using 100 cutaneous
wart swabs previously characterized for HPV by the HSL-PCR/
MPG assay, are reported.
MATERIALS AND METHODS
Wart samples. The panel of clinical samples consisted of swabs taken from 100
cutaneous warts derived from 100 individuals (ages, 4 years) with one or more
cutaneous warts who self-presented to their general practitioner (1). The swabs
were taken from one wart from each patient by firmly rubbing a prewetted
cotton-tipped stick 5 times over the surface of the lesion. Next, the swabs were
put in 1 ml of 0.9% sodium chloride. Portions of 10 l were used directly in the
PCRs for both genotyping assays.
Plasmid clones. The analytic sensitivity and specificity of the BSwart assay
were determined for each HPV type using DNA from plasmids containing the
full-length HPV prototype genome after purification by the Plasmid Midi kit
(Qiagen). For HPV types 91 and 94, no full-length genome was available and a
fragment comprising 300 bp of the L1 gene was synthesized (Eurofins MWG
Operon, Ebersberg, Germany). For determination of the analytic sensitivity,
plasmid preparations were quantified using NanoDrop ND-1000 (NanoDrop
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Technologies, Wilmington, DE). Copy numbers were determined on the basis of
the molecular weights of the plasmids. Endpoint dilution series (10-fold) were
prepared in 100 ng/l of human placenta DNA in a total volume of 30 l. For
colony PCR, picked DH5 bacteria, transformed by high-copy-number plasmids
containing the viral genome, were used directly as a PCR template.
BSwart-PCR/MPG assay. The BSwart-PCR/MPG assay comprises the
BSwart-PCR generating a biotinylated amplimer of 145 to 148 bp from the L1
region and a genotyping assay with bead-based xMAP Luminex suspension array
technology, which is able to simultaneously identify 19 wart-associated HPV
types from the alpha (HPV2, -3, -6, -7, -10, -11, -27, -28, -29, -40, -43, -57, -77, -91,
-94, and -117), mu (HPV1 and -63), and nu (HPV41) genera. In total, 10 forward
and 8 biotinylated reverse PCR primers were used as described by the manu-
facturer (Steinbeis Transfer Centre Multiplexion, Heidelberg, Germany). Inter-
nal DNA and PCR quality was assessed by coamplifying the human -globin
sequence (10).
Briefly, the 50-l reactions comprised 1 Multiplex PCR kit buffer (Qiagen,
Hilden, Germany), containing 3.5 mM MgCl2, deoxynucleoside triphosphate
(dNTP) mix, HotStartTaq DNA polymerase, 0.2 M each HPV primer, and 10
l of sample DNA or 1 l of HPV plasmid dilutions. A 15-min enzyme activation
step at 95°C was followed by 40 cycles of amplification in a Mastercycler (Ep-
pendorf, Hamburg, Germany). Each cycle included a denaturation step at 94°C
for 20 s, an annealing step at 38°C for 30 s, and an elongation step at 71°C for
80 s. The final elongation step was prolonged for a further 4 min. Ramping rates
for the Mastercycler were adjusted as described recently (13): 1.8°C/s from 94°C
to 38°C, 2.0°C/s from 38°C to 71°C, and 2.8°C/s from 71°C to 94°C. Each PCR
experiment included samples with reference plasmids as positive controls and
several samples lacking template DNA as negative controls.
Following PCR amplification, 10 l of each reaction mixture was transferred
to 96-well plates containing, in each well, 33 l of tetramethylammonium chlo-
ride (TMAC) hybridization solution (0.15 mol/liter TMAC, 75 mmol/liter Tris-
HCl, 6 mmol/liter EDTA, 1.5 g/liter Sarkosyl, pH 8.0), 7.0 l of 1 Tris-EDTA
(TE), and a mixture of 2,000 probe-coupled beads of each set as described
recently for BSGP5/6-PCR/MPG, an assay for genotyping mucosal genus
alpha HPV types (7–9). The mixture was heated to 95°C for 10 min, immediately
placed on ice for 1 min, and then moved to a thermomixer for hybridization at
41°C for 30 min under agitation. The samples were transferred to a 96-well wash
plate (Millipore, Bedford, MA), preequilibrated with washing buffer (phosphate-
buffered saline [PBS], 0.02% Tween). Subsequently, the beads were washed once
with 100 l of washing buffer on a vacuum wash station (Millipore, Bedford,
MA). On a horizontal shaker at room temperature, beads were resuspended for
20 min in 50 l of streptavidin-R-phycoerythrin (Molecular Probes, Eugene,
OR) diluted 1:1,600 in 2.0 mol/liter TMAC, 75 mmol/liter Tris-HCl, 6 mmol/liter
EDTA, 1.5 g/liter Sarkosyl, pH 8.0. Beads were then washed three times with 100
l washing buffer and finally resuspended in 100 l washing buffer for 5 min on
a shaker. Beads were analyzed for internal bead color and R-phycoerythrin
reporter fluorescence on a Luminex 100 analyzer. The median reporter fluores-
cence intensity (MFI) of at least 100 beads was computed for each bead set in the
sample.
BSwart cutoff definition and statistics. For each BSwart probe, MFI values
from PCRs with no template (about 10% of all reactions) were considered
background values. For each experiment, the cutoff was computed by adding 5
MFI to 1.2 times the median background value, as described recently (9). For all
probes, this cutoff value was above the mean background plus three times the
standard deviation. Due to potential cross-reactions of the HPV2 probe with
HPV27 PCR products, signals of the HPV2 probe were excluded when they were
lower than 12% of the HPV27 probe. HPV- and -globin-negative samples by
the BSwart assay were excluded from the analysis due to poor DNA quality.
Type-specific detection differences between the two genotyping assays were as-
sessed by chi-square tests.
HSL-PCR/MPG assay. The HSL-PCR/MPG assay was performed as described
by the manufacturer (Labo Biomedical Products BV, Rijswijk, Netherlands).
Briefly, it comprises a primer set with 27 nondegenerate primers (13 forward and
14 reverse) generating a biotinylated amplimer of 76 to 84 bp from the L1 region
upstream of the BSwart amplification region in 35 amplification cycles.
Genotyping is performed with bead-based xMAP suspension array technology,
which is able to simultaneously identify 23 wart-associated HPV types from the
alpha (HPV2, -3, -7, -10, -27, -28, -29, -40, -43, -57, -77, -91, and -94), gamma
(HPV4, -65, -95, -48, -50, -60, and -88), mu (HPV1 and -63), and nu (HPV41)
genera (1). The assay design results in very low nonspecific background signals
and therefore requires no background subtraction. The cutoffs were applied as
described before (1).
RESULTS
Analytic sensitivity and dose response. The analytic sensi-
tivity of the multiplex HPV primers was determined for all
HPV types included in the assay, except for HPV types 11 and
117, using 10-fold dilution series of plasmids containing viral
L1 DNA in the presence of 100 ng/l of human placenta DNA.
BSwart detected all HPV genotypes analyzed, with an analytic
sensitivity of between 100 and 10 copies of the viral genome
per PCR (Table 1). Semiquantitative HPV detection was pos-
sible with various degrees of efficiency over several orders of
magnitude (Fig. 1). The -globin detection limit reached 0.1 ng
of genomic DNA (17 cell equivalents). The simultaneous co-
amplification of -globin did not influence the detection limit
for HPV (data not shown).
Specificity. Specificity of the bead-coupled oligonucleotide
probes was determined by hybridizing PCR products obtained
from all 19 HPV genotypes and -globin to a bead mixture
comprising all specific probes (Table 2). To reduce the possible
risk of contamination during plasmid purification, bacterial
cells previously transformed with individual HPV genomes
were used as a template directly (an estimated 109 plasmid
copies), instead of diluted HPV plasmid DNA. Highly specific
signals were observed for all 19 HPV type-specific probes with
the respective PCR products (Table 2). Only the HPV2 probe
weakly cross-reacted with the HPV27 PCR products.
Comparison of BSwart with HSL-PCR/MPG. In total, 8 of
the 100 wart swabs were HPV negative by one of the assays
(Table 3). Two samples that were positive by the HSL-PCR/
MPG assays were negative for HPV and -globin detection by
the BSwart assay. Three wart swabs were found to be HPV
positive only by the BSwart assay, whereas five wart swabs were
HPV positive only with the HSL-PCR/MPG. Of these five,
three contained gamma HPV types not included in the BSwart
assay (Table 3).
Next, we compared the detection of 16 HPV types that were
detected by both the BSwart and the HSL-PCR/MPG assay.
The HPV prevalence determined by the two methods is pre-
sented in Table 4. Using BSwart, 95 of the 100 samples (95%)
TABLE 1. HPV type detection limits of BSwart-PCR/MPG with
integrated -globin detection


















a Detection limit is defined as the number of plasmid copies in 100 ng human
placenta DNA.
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were HPV positive and five samples were HPV negative. The
most prevalent type found in the 100 warts was HPV1 (n  40;
40.0%; genus mu, species 1) followed by HPV27 (n  38;
38.0%), HPV57 (n  24; 24.0%), and HPV2 (n  22; 22.0%;
genus alpha, species 4). With the HSL-PCR/MPG, 92 of the
100 samples were positive (92%); however, the result increased
to 98% when HPV types of the genus gamma were also ana-
lyzed. The most prevalent HPV types were HPV1 (n  30;
FIG. 1. Analytic sensitivity and dose response of BSwart-PCR/MPG for HPV1, -10, -27, -28, -41, and -57. Dilution series (10-fold) of plasmids
containing genomic HPV DNA, diluted in 100 ng of human placenta DNA, were analyzed in duplicates by BSwart-PCR/MPG. Means and standard
errors of results from two amplification and hybridization reactions are indicated.




Signala detected with bead-coupled oligonucleotide probe for HPV type:
1 2 3 6 7 10 11 27 28 29 40 41 43 57 63 77 91 94 117 -globin
1 887 0b 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2 0 1,041 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
3 0 0 937 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
6 0 0 0 326 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 0 0 0 0 949 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10 0 0 0 0 1 716 0 0 0 0 0 0 0 1 0 0 0 3 0 1
11 0 0 0 0 0 0 839 0 0 0 0 0 0 0 0 0 0 0 0 0
27 0 19c 0 1 0 0 0 743 1 1 0 0 0 0 0 0 0 0 0 0
28 0 0 0 1 0 0 0 1 629 0 0 0 0 0 0 0 0 0 0 0
29 0 0 0 1 0 0 0 0 0 1,042 0 0 0 0 1 0 0 0 0 0
40 0 0 0 0 1 0 0 0 0 1 564 0 0 0 1 0 0 0 0 0
41 0 0 0 0 0 0 0 0 0 0 0 996 0 0 0 0 0 0 0 0
43 0 0 0 0 0 0 0 0 0 0 0 0 452 0 1 0 0 0 0 0
57 0 1 0 1 1 0 0 0 0 0 0 0 0 1,018 0 0 1 0 0 0
63 0 0 0 0 0 0 0 0 0 0 0 0 0 0 841 0 0 0 0 0
77 0 0 0 1 0 1 0 0 0 0 0 0 1 1 0 934 1 0 0 0
91 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 819 0 0 0
94 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 2,452 0 0
117 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1,482 0
-Globin 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 408
a Specific signal (bold) is given as net median fluorescence intensity (net MFI) after the subtraction of 1.2 times the median probe-dependent background value.
Cutoff was 5 net MFI.
b Background generated from PCR products that did not hybridize to the respective probe.
c Weak cross-reactivity of the HPV2 probe with HPV27 PCR product.
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30.0%), HPV27 (n  31; 31.0%), HPV2 (n  20; 20.0%), and
HPV57 (n  15; 15.0%).
The difference between the two assays was particularly evi-
dent for the detection of HPV types 1 (P  0.05), 10 (P 
0.05), 27 (P  0.05), 28 (P  0.01), 41 (P  0.05), 57 (P 
0.05), and 63 (P  0.05) (Table 4), which were at least 22%
more frequently detected by BSwart. In cases where weak
signals for HPV types 1, 27, and 28 were detected only by
BSwart (Fig. 2), the signal intensity corresponded to 10 to 100
HPV copy numbers per PCR compared to external standard
curves (Fig. 1). However, for HPV41 (4 of 5), HPV10 (4 of 6),
and HPV57 (1 of 11), additional BSwart reactions corre-
sponded to 100 to 10,000 copy numbers per PCR (Fig. 2).
The majority of additional reactions were detected in mul-
tiple infections. As tested by HSL-PCR/MPG, 84 (91.3%) of
the 92 positive wart samples for common HPV types exhibited
single infections, 7 (7.6%) double infections, and 1 (1.1%)
triple infection. When HPV types of the genus gamma were
also included, 86 single infections (88.7%), 10 double infec-
tions (10.3%), and one triple infection (1.0%) were detected.
In contrast, using BSwart, 95 warts were positive with 51
(53.7%) single, 34 (35.8%) double, 6 (6.3%) triple, 3 (3.2%)
quadruple, and 1 (1.1%) sextuple infections.
Overall concordance between the two assays. The number of
specimens and HPV types analyzed by both methods corre-
sponded to a total of 1,600 signals by each method. Of these, 94
signals were concordantly positive (6.0%) and 1,438 concor-
dantly negative (89.8%). In addition, 61 (3.8%) and 7 (0.4%)
reactions additionally detected by BSwart and HSL-PCR/
MPG, respectively, were discordant. This yielded a kappa
value of 0.71 (95% confidence interval, 0.65 to 0.78).
Concordance in detecting dominant HPV genotypes. The
intensities of MFI signals for each HPV type in a multiple
infection reflect the relative concentrations of targets included
in the PCR (8). For all positive reactions, positive signals were
normalized to the maximum signals observed either in this
study (HSL-PCR/MPG) or in the specificity experiment
(BSwart). The HPV type with the highest relative value was
defined as the dominant type. Among the 100 samples, 3
(3.0%) were concordantly negative, 86 (86.0%) were concor-
dantly positive with the same dominant HPV type, and 11
(11%) were discordant. This indicated an excellent agreement
between the two methods for identifying a dominant HPV type
in single and multiple infections and resulted in a total con-
cordance of 89.0%.
DISCUSSION
The novel BSwart HPV genotyping assay employed mostly
broad-spectrum primers and facilitated the simultaneous and
highly specific DNA detection of all 19 HPV skin wart types.
The analytic sensitivity reached the level of 10 to 100 copies
per PCR. The quantitative data output of the high-throughput
assay avoided manual processing of the data.
Both the BSwart and HSL-PCR/MPG assay provide a so-far
unique ability to genotype all genus alpha, mu, and nu cuta-
neous HPV types. The BSwart assay could also detect addi-
tionally the genus alpha HPV types 6, 11, and 117, while HSL-
PCR/MPG identifies additionally the genus gamma HPV types
4, 48, 50, 60, 65, 88, and 95. The simultaneous detection of
genus gamma HPV types by the BSwart assay was not envi-
sioned, because we developed in parallel a novel multiplex
cutaneous papillomavirus genotyping (McPG) assay at the
DKFZ, which is capable of genotyping all 38 currently defined
and 20 putative cutaneous HPV of the genera beta, gamma,
mu, and nu (5a).
In comparison to the recently described HSL-PCR/MPG
assay, the BSwart method showed a higher sensitivity in de-
tecting various HPV types of the genus alpha, mu, and nu in
plasmid dilution series as well as clinical specimens. The semi-
quantitative results (Fig. 1) confirmed that most of the addi-
tionally detected HPV types were present with low viral loads.
As the clinical samples were preselected for HPV positivity,
the increased sensitivity resulted mostly in the detection of
multiple HPV types. The 35 HSL-PCR cycles (while the
TABLE 4. Detection of HPV genotypes in 100 wart samples by
BSwart (BS)- or HSL-PCR/MPG (HSL)
HPV type
No. of positive reactionsa
BS/HSL	 BS	/HSL BS and HSL BS and/or HSL
1 12 3 28 43
2 4 2 18 24
3 2 2 4
7 1 1
10 6 6






57 11 2 13 26




Total 61 7 94 162
a Number of positive reactions for given HPV type. For example, from a total
of 24 HPV2-positive samples, 18 were detected by both methods, and 4 and 2
additional reactions were detected by BSwart and HSL-PCR/MPG, respectively.
HPV6, -11, and -117 were included only in the BSwart assay and showed no
positive reaction. Of the HPV types included only in the HSL-PCR/MPG assay
(HPV4, -48, -50, -60, -65, -88, and -95), HPV4 (n  5), -65 (n  1), and -95 (n 
1) were detected, in 4 cases as a single infection.
TABLE 3. Negative samples by either BSwart- or HSL-PCR/MPG
Sample




1 pos 10, 28 neg
2 pos 94 neg
3 pos 1 neg
4 neg neg 57
5 pos neg 95
6 pos neg 65
7 pos neg 4
8 neg neg 1, 4
a pos, positive; neg, negative.
b Genotypes indicated in bold font are included in both assays.
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BSwart uses 40 cycles), the use of different PCR reagents and
primers, and distinct cutoffs for interpretation of Luminex re-
sults are likely to cause the difference seen in the analytical
sensitivity. By lowering the cutoff of the HSL-PCR/MPG assay,
a higher concordance between the two assays for HPV types 1,
10, and 57 was observed (data not shown).
Taking advantage of the semiquantitative results of the
BSwart assay, multiple HPV infections could be better char-
acterized. Accordingly, the dominant HPV type and, thus, the
genotype with the potentially highest viral load could be de-
termined. In the vast majority of samples (89.0%), the domi-
nant type, as determined by BSwart, was identical to the HPV
type identified in the single infections by the HSL-PCR/MPG
assay. Consequently, the two assays showed an excellent con-
cordance and appeared to be able to identify the HPV type
with the potentially highest viral load. It is very likely that these
dominant types are also the biologically most active and, thus,
the driving force in the development of skin warts.
A difference was seen in the abilities of the two assays to
detect multiple HPV types in the same sample. The presence
of multiple infections was surprising, as the swab specimens
were taken directly from the top of warts and, thus, were
expected to be positive for only one type. Nonetheless, BSwart
identified a large fraction of these samples with multiple in-
fections. The presence of different HPV genotypes in a single
sample could suggest that natural competition of different
HPV types may not occur on the skin. Hitherto, it was un-
known whether these different viruses are present in the same
cell, whether the wart is caused only by one type while addi-
tional viruses are passengers, and whether these passengers are
biologically active. Viruses with apparently no detectable bio-
logical activity, however, may hint at latency in the viral life
cycle consequent to evasion from the immune system. None-
theless, by determining the dominant HPV type, the two meth-
ods agreed in 89% of cases, indicating that mostly one type is
probably driving the lesion. However, in three multiple infec-
tions, two HPV types were identified by BSwart with similarly
high signal intensities, suggesting that both HPV types might
play a role in the development of these warts. This finding was
confirmed by HSL-PCR/MPG and might be explained by the
possible presence of adjacent warts caused by different HPV
types in these three cases.
Identifying the individual HPV types in cutaneous warts is
important for cutaneous genus alpha HPV vaccine strategies.
These data are required to determine which HPV types should
be included in the future vaccines and to estimate the efficacy
of these vaccines in immunocompromised patients.
In conclusion, both the novel BSwart and HSL-PCR/MPG
genotyping assays are powerful high-throughput tools that
could be used to learn more about the natural history of genus
alpha, mu, and nu skin HPV types.
ACKNOWLEDGMENTS
HPV1, -2, -3, -6, -7, -11, -27, -40, -41, -57, -63, and -77 plasmid DNA
were kindly provided by E.-M. de Villiers (DKFZ, Heidelberg, Ger-
many), HPV10, -28, and -29 by M. Favre (Institut Pasteur, Paris,
France), HPV43 by A. Lörincz (Digene Corp., Gaithersburg, MD),
HPV91 by R. Burk (Albert Einstein College of Medicine of Yeshiva
University, New York), and HPV117 by I. Nindl (DKFZ, Heidelberg,
Germany). We thank Eva Tritsch and Daniela Höfler for experimental
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BSwart-PCR/MPG (x axis) are plotted against the HSL-PCR/MPG signals (y axis) using double logarithmic scales. The cutoffs are indicated by the
dashed lines.
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